Definium Therapeutics NASDAQ: DFTX expects to file a new drug application for its lead LSD-based treatment in the first half of 2027, though the company has not settled on whether to seek approval for generalized anxiety disorder, major depressive disorder or both at the outset.
CEO Rob Barrow said at the Jefferies London Healthcare Conference that Definium plans to provide more detail on its filing strategy after receiving minutes from a pre-application meeting with the U.S. Food and Drug Administration. He did not say whether that meeting had already taken place.
The company’s lead program, DT120, is a proprietary orally disintegrating tablet of LSD. Barrow said Definium reported three positive pivotal study readouts over the summer: two in generalized anxiety disorder and one in major depressive disorder. A fourth pivotal study, the second in depression, is expected to read out in 2027, although he did not narrow the timing.
Several Filing Paths Under Consideration
Barrow said Definium’s goal is to launch DT120 with both conditions on its label, subject to approval. The company could file for both indications concurrently, pursue its original plan of seeking an anxiety approval first and a supplemental application for depression later, or stagger the submissions while still aiming for a joint launch, he said.
The decision also intersects with the timing of the second depression study and the desire to present the strongest evidence package to regulators and clinicians, Barrow said. He noted that a controlled substance requires Drug Enforcement Administration scheduling action after approval before it can be marketed.
Definium is compiling the data needed for its application, Barrow said. He added that the company has had frequent discussions with the FDA and has Breakthrough Therapy designation for both programs.
Dosing, Monitoring and Market Opportunity
Barrow described a potential treatment approach in which patients receive a dose and are monitored for returning symptoms, with subsequent doses available when needed. In the studies’ nine-month open-label extension phase, patients could receive up to four additional doses if moderate or worse symptoms returned.
Based on data presented so far, about a quarter of observed patients had a long-lasting effect from one dose, Barrow said. He said the vast majority appeared to fall within a range of one to three doses, although the most extensive data disclosed so far covered six months. More data will be shared in the future, he said.
Patients in the studies spent an average of about six hours under observation before being considered safe to go home, according to Barrow. He said Definium expects a risk-management framework structurally similar to that of Johnson & Johnson’s Spravato, while acknowledging that the FDA will determine the requirements.
In Definium’s trials, one person was in the room with each patient, and another person typically watched by video from the site, Barrow said. Most in-room monitors were licensed clinical social workers.
Definium has not announced a price for DT120. Barrow cited Spravato, an intranasal esketamine treatment, as an imperfect pricing comparison, saying its annual price range is roughly $30,000 to $70,000. He contrasted Spravato’s potential for up to 56 doses a year with the few doses Definium expects many DT120 patients to need.
Second Program Advances
Definium is also developing DT402, an R-MDMA program for autism spectrum disorder. Barrow said the company saw a signal in the first five patients of an open-label study designed to enroll up to 20 patients.
Unlike DT120, DT402 is being developed more like a psychostimulant model used in attention-deficit/hyperactivity disorder, rather than as a single intervention intended to produce long-lasting benefit, Barrow said. He said more work is needed to optimize the dose and regimen and assess whether benefits can be sustained.
About Definium Therapeutics (NASDAQ:DFTX)
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Definium Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definium Therapeutics wasn't on the list.
While Definium Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.